While large-molecule therapeutics capture most headlines, small-molecule drugs face significant challenges, struggling with funding cuts, supply chain disruptions, and growing demand. At the same time ...
The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...
Terray Therapeutics, a biotechnology company using artificial intelligence to accelerate the development of small-molecule drugs, said today it has raised $120 million in a Series B fundraise to ...
The "U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Customer Type, Therapeutic Area, Region, and Segment ...
Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...
While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development continue to face a multitude of obstacles, such as complex methodologies, high ...
Washington, DC, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Today, Incubate launched the "Small Molecules, Big Voices" video series to illustrate the importance of small molecule drugs to patients, investors, ...
Dec 3 (Reuters) - Excelsior Sciences said on Wednesday it has raised $95 million to develop technology that uses machines and artificial intelligence to accelerate the development and testing of small ...
LOS ANGELES--(BUSINESS WIRE)--Terray Therapeutics, a biotechnology company improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation ...
Eli Lilly and Co. is collaborating with Boston-based Superluminal Medicines to use artificial intelligence to discover small-molecule drugs for cardiometabolic disease and obesity in an agreement ...
GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback